Refine
Document Type
- Article (83)
Has Fulltext
- yes (83) (remove)
Is part of the Bibliography
- no (83)
Keywords
- prostate cancer (21)
- radical prostatectomy (14)
- bladder cancer (11)
- growth (6)
- integrins (6)
- Prostate cancer (5)
- chemotherapy (4)
- curcumin (4)
- external beam radiotherapy (4)
- invasion (4)
- metastatic prostate cancer (4)
- mortality (4)
- sulforaphane (4)
- 177Lu-PSMA-617 (3)
- Adenocarcinoma (3)
- FFLU (3)
- PSMA (3)
- Squamous cell carcinoma (3)
- Variant histology (3)
- primary prostate cancer (3)
- proliferation (3)
- survival (3)
- systematic biopsy (3)
- Bladder cancer (2)
- CD44 (2)
- CSM (2)
- Cancer-specific mortality (2)
- Epidemiology and End Results (2)
- Gleason score (2)
- HoLEP (2)
- Melanoma (2)
- PSA (2)
- Penile cancer (2)
- Radical prostatectomy (2)
- SCC (2)
- Surveillance (2)
- Urethral cancer (2)
- adhesion (2)
- cancer specific survival (2)
- cancer-specific mortality (2)
- concordance (2)
- contemporary (2)
- functional outcome (2)
- fusion biopsy (2)
- immunohistochemistry (2)
- intermediate risk (2)
- kidney cancer (2)
- localized prostate cancer (2)
- lymph node dissection (2)
- mTOR (2)
- other-cause mortality (2)
- outcomes (2)
- overall survival (2)
- radical cystectomy (2)
- radical prostatecomy (2)
- renal cell cancer (2)
- resistance (2)
- salvage radical prostatectomy (2)
- tumor growth (2)
- upgrading (2)
- urological cancer (2)
- 223Radium-dichloride (1)
- AKT-mTOR pathway (1)
- ASAP (1)
- Acute kidney injury (1)
- Akt-mTOR pathway (1)
- Akt-mTOR signaling (1)
- Anticoagulation (1)
- Artificial intelligence (1)
- Awareness campaign (1)
- BMI (1)
- BPH (1)
- BPO (1)
- Bleeding (1)
- CDK-cyclin axis (1)
- CRPC (1)
- Cancer check up (1)
- Cancer therapy (1)
- Cancer-specific survival (1)
- Checkpoint inhibitor (1)
- Chemoprevention (1)
- Clavien–Dindo classification (1)
- Complications (1)
- Cystatin C (1)
- Cytoreductive nephrectomy (1)
- Dietary HDAC inhibitor (1)
- Downgrading (1)
- D’Amico classification (1)
- EBRT (1)
- External beam radiotherapy (1)
- Extraprostatic (1)
- Functional outcomes (1)
- GFR (1)
- Geographical disparities (1)
- Gleason Grade group (1)
- Gleason Score (1)
- Gleason grade group (1)
- Gleason upgrading (1)
- HDAC (1)
- HOLEP (1)
- Hematologic adverse events (1)
- Hematotoxicity (1)
- High-risk prostate cancer (1)
- Hispanic–Latino race/ethnicity (1)
- Histology (1)
- Holmium laser enucleation (1)
- IGF-1 (1)
- IHC (1)
- IPSS (1)
- Immunotherapy (1)
- Incidence rate (1)
- Incidental prostate cancer (1)
- Inferior vena cava thrombus (1)
- Intermediate-risk (1)
- Keap1-Nrf2 (1)
- Lee type, functional outcome (1)
- Lee-type (1)
- Local therapy (1)
- Locally advanced (1)
- Long-term continence (1)
- Machine learning (1)
- Metastasis-directed therapy (1)
- Metastatic castration-resistant prostate cancer (1)
- Metastatic renal cell carcinoma (1)
- Mortality (1)
- Multiparametric MRI (1)
- NCCN (1)
- NIS (1)
- NVBP (1)
- Nephrectomy (1)
- NeuroSAFE (1)
- Nivolumab (1)
- Non-urothelial (1)
- OR time (1)
- ORP (1)
- Oligometastatic (1)
- Organ-confined (1)
- PAD-test (1)
- PD-1 inhibitor (1)
- PROM (1)
- PSA screening (1)
- PSA-Screening (1)
- Positron-emission tomography (1)
- Preventive medicine (1)
- Prostata-specific antigen (1)
- Prostataspezifisches Antigen (1)
- Prostate-specific membrane antigen (1)
- Prostatic neoplasms (1)
- Prävention (1)
- QOL (1)
- RARP (1)
- ROS (1)
- Race (1)
- Radical cystectomy (1)
- Radiomics (1)
- Radiotherapy (1)
- Region (1)
- Renal cell carcinoma (1)
- Renal vein thrombus (1)
- Robotic-assisted radical prostatectomy (1)
- SEER (1)
- Salvage therapy (1)
- Single positive core biopsy (1)
- Social differences (1)
- Stage at presentation (1)
- Sulphoraphane (1)
- Systemic therapy (1)
- TUR-P (1)
- Time trend (1)
- Transfusion (1)
- Transitional cell carcinoma (1)
- Transurethral resection of the prostate (1)
- Treatment rates (1)
- Upgrading (1)
- Urinary continence (1)
- Urinary incontinence (1)
- Urologic tumors (1)
- Urothelial cancer (1)
- Vorsorgeuntersuchung (1)
- adjuvant chemotherapy (1)
- amygdalin (1)
- antibiotic treatment (1)
- apex (1)
- bioavailability (1)
- biopsy (1)
- biopsy naïve (1)
- blood loss (1)
- bone barrow (1)
- buccal mucosal graft urethroplasty (1)
- cabazitaxel (1)
- cabozantinib (1)
- cancer-specific survival (1)
- castration resistance (1)
- catheter (1)
- catheter removal (1)
- cdk (1)
- cell cycling (1)
- cell growth (1)
- cellular heterogeneity (1)
- chemoprotection (1)
- chemoresistance (1)
- chemotaxis (1)
- clinical node positive (1)
- colon cancer (1)
- complementary/alternative medicine (CAM) (1)
- complication (1)
- complications (1)
- consensus classification (1)
- correlation (1)
- cost analysis (1)
- cyclins (1)
- deferred treatment (1)
- delayed treatment (1)
- diffuse marrow involvement (1)
- docetaxel (1)
- double negative (1)
- downgrading (1)
- drug resistance (1)
- early continence (1)
- elderly (1)
- endothelial cells (1)
- epididymitis (1)
- ethnicity (1)
- everolimus (1)
- heart (1)
- hepatocellular carcinoma (1)
- high-risk (1)
- histological outcomes (1)
- histone deacetylase (1)
- human (1)
- incontinence (1)
- infection (1)
- inverse stage migration (1)
- kidney (1)
- length of stay (1)
- light irradiation (1)
- liver (1)
- local treatment (1)
- low risk (1)
- lung cancer (1)
- lymph node metastases (1)
- mCRPC (1)
- mechanistic target of rapamycin (mTOR) (1)
- membranous urethra (1)
- metastasis (1)
- metastatic castration-resistant prostate cancer (1)
- metastatic urethral cancer (1)
- mid-term urinary continence (1)
- molecular subtyping (1)
- mpMRI (1)
- mtor (1)
- multiparametric magnetic resonance imaging (1)
- neoadjuvant chemotherapy (1)
- nerve-sparing (1)
- nerve-sparing surgery (1)
- neurovascular bundle preservation (1)
- non-organ confined stage (1)
- olive mill wastewater (OMWW) (1)
- open (1)
- other cause mortality (1)
- overtreatment (1)
- oxidative stress (1)
- pad-test (1)
- patient-reported outcome measure (1)
- perioperative outcome (1)
- post-radiotherapy recurrence (1)
- predictor (1)
- prehabilitation (1)
- prognosis (1)
- prostate neoplasm (1)
- prostate volume (1)
- prostate-specific antigen (1)
- race (1)
- race/ethnicity disparities (1)
- radiation (1)
- renal cell carcinoma (1)
- repeat biopsy (1)
- resistant cell lines (1)
- risk score (1)
- robotic-assisted (1)
- second-line (1)
- secondary cancer (1)
- sexual dysfunction (1)
- sexual rehabilitation (1)
- single-cell proteomics (1)
- stage (1)
- suprapubic catheter (1)
- surgical complications (1)
- surgical margin (1)
- targeted biopsy (1)
- temsirolimus (1)
- temsirolimus-resistance (1)
- transrectal prostate biopsy (1)
- transurethral catheter (1)
- tumor adhesion (1)
- tumor migration (1)
- tumor proliferation (1)
- tumor weight (1)
- tyrosine kinase inhibitors (1)
- upstaging (1)
- urethral stricture (1)
- urethroplasty (1)
- urinary incontinence (1)
- valproic acid (1)
- very high risk (1)
- very high-risk (1)
- waiting time (1)
- Öffentlichkeit (1)
Institute
- Medizin (83)
- Biowissenschaften (1)
- Informatik und Mathematik (1)
The effect of race/ethnicity on cancer-specific mortality after salvage radical prostatectomy
(2022)
Background: To test the effect of race/ethnicity on cancer-specific mortality (CSM) after salvage radical prostatectomy (SRP).
Material and methods: We relied on the Surveillance, Epidemiology and End Results database (SEER, 2004–2016) to identify SRP patients of all race/ethnicity background. Univariate and multivariate Cox regression models addressed CSM according to race/ethnicity.
Results: Of 426 assessable SRP patients, Caucasians accounted for 299 (69.9%) vs. 68 (15.9%) African-Americans vs. 39 (9.1%) Hispanics vs. 20 (4.7%) Asians. At diagnosis, African-Americans (64 years) were younger than Caucasians (66 years), but not younger than Hispanics (66 years) and Asians (67 years). PSA at diagnosis was significantly higher in African-Americans (13.2 ng/ml), Hispanics (13.0 ng/ml), and Asians (12.2 ng/ml) than in Caucasians (7.8 ng/ml, p = 0.01). Moreover, the distribution of African-Americans (10.3%–36.6%) and Hispanics (0%–15.8%) varied according to SEER region. The 10-year CSM was 46.5% in African-Americans vs. 22.4% in Caucasians vs. 15.4% in Hispanics vs. 15.0% in Asians. After multivariate adjustment (for age, clinical T stage, lymph node dissection status), African-American race/ethnicity was an independent predictor of higher CSM (HR: 2.2, p < 0.01), but not Hispanic or Asian race/ethnicity. The independent effect of African-American race/ethnicity did not persist after further adjustment for PSA.
Conclusion: African-Americans treated with SRP are at higher risk of CSM than other racial/ethnic groups and also exhibited the highest baseline PSA. The independent effect of African-American race/ethnicity on higher CSM no longer applies after PSA adjustment since higher PSA represents a distinguishing feature in African-American patients.
Aim: To compare overall mortality (OM), cancer-specific mortality (CSM), and other cause mortality (OCM) rates between radical prostatectomy (RP) versus radiotherapy (RT) in clinical node-positive (cN1) prostate cancer (PCa).
Materials and Methods: Within Surveillance, Epidemiology, End Results (SEER) (2004–2016), we identified 4685 cN1 PCa patients, of whom 3589 (76.6%) versus 1096 (24.4%) were treated with RP versus RT. After 1:1 propensity score matching (PSM), Kaplan–Meier plots and Cox regression models tested the effect of RP versus RT on OM, while cumulative incidence plots and competing-risks regression (CRR) models addressed CSM and OCM between RP and RT patients. All analyses were repeated after the inverse probability of treatment weighting (IPTW). For CSM and OCM analyses, the propensity score was used as a covariate in the regression model.
Results: Overall, RT patients were older, harbored higher prostate-specific antigen values, higher clinical T and higher Gleason grade groups. PSM resulted in two equally sized groups of 894 RP versus 894 RT patients. After PSM, 5-year OM, CSM, and OCM rates were, respectively, 15.4% versus 25%, 9.3% versus 17%, and 6.1% versus 8% for RP versus RT (all p < 0.001) and yielded respective multivariate hazard ratios (HRs) of 0.63 (0.52–0.78, p < 0.001), 0.66 (0.52–0.86, p < 0.001), 0.71 (0.5–1.0, p = 0.05), all favoring RP. After IPTW, Cox regression models yielded HR of 0.55 (95% confidence interval [CI] = 0.46–0.66) for OM, and CRR yielded HRs of 0.49 (0.34–0.70) and 0.54 (0.36–0.79) for, respectively, CSM and OCM, all favoring RP (all p < 0.001).
Conclusions: RP may hold a CSM advantage over RT in cN1 PCa patients.
Background: Survival data regarding cytoreductive nephrectomy (CN) in metastatic renal cell carcinoma (mRCC) patients according to the type and extent of tumor-associated vascular thrombus are scarce.
Objective: To test for survival differences in mRCC patients treated with CN according to the type and extent of tumor-associated vascular thrombus.
Design, setting, and participants: Within Surveillance, Epidemiology, and End Results Research Plus (2004–2017), we identified CN mRCC patients with renal vein (pT3a-TT) versus infradiaphragmatic inferior vena cava (IVC; pT3b) versus supradiaphragmatic IVC tumor thrombus/IVC invasion (pT3c).
Outcome measurements and statistical analysis: Overall survival (OS) was addressed in Kaplan-Meier and Cox regression analyses, in addition to 3-mo landmark analyses.
Results and limitations: Of 2170 mRCC patients, 1880 (87%), 204 (9%), and 86 (4%) harbored pT3a-TT, pT3b, and pT3c, respectively. The respective median OS periods were 21, 23, and 12 mo (p < 0.001). In multivariable Cox regression models, pT3c stage, but not pT3b stage, was an independent predictor of higher overall mortality (hazard ratio [HR]: 1.37; 95% confidence interval [CI]: 1.09–1.73; p = 0.007), as well as in 6-mo landmark analyses (HR: 1.36; 95% CI: 1.02–1.80; p = 0.04). In the sensitivity analysis, relying on all pT3a patients, the predictor status of pT3c stage remained unchanged (HR: 1.37; 95% CI: 1.09–1.71; p = 0.007). Limitations have to be addressed regarding the sample size and the retrospective design of the current study.
Conclusions: Although overall mortality is significantly higher in pT3c mRCC patients than in their pT3b and pT3a-TT counterparts, these individuals may still expect 12-mo or better OS after CN versus virtually 2-yr OS in their pT3a and pT3b counterparts.
Patient summary: In this study, we looked at the survival outcomes of metastatic renal cell carcinoma patients who presented with tumor thrombus at cytoreductive nephrectomy. Even though these patients with most advanced tumor thrombus stage demonstrated lower survival rates, the median overall survival was still 1 yr.
Background: To test the impact of urethral sphincter length (USL) and anatomic variants of prostatic apex (Lee-type classification) in preoperative multiparametric magnet resonance imaging (mpMRI) on mid-term continence in prostate cancer patients treated with radical prostatectomy (RP). Methods: We relied on an institutional tertiary-care database to identify patients who underwent RP between 03/2018 and 12/2019 with preoperative mpMRI and data available on mid-term (>6 months post-surgery) urinary continence, defined as usage 0/1 (-safety) pad/24 h. Univariable and multivariable logistic regression models were fitted to test for predictor status of USL and prostatic apex variants, defined in mpMRI measurements. Results: Of 68 eligible patients, rate of mid-term urinary continence was 81% (n = 55). Median coronal (15.1 vs. 12.5 mm) and sagittal (15.4 vs. 11.1 mm) USL were longer in patients reporting urinary continence in mid-term follow-up (both p < 0.01). No difference was recorded for prostatic apex variants distribution (Lee-type) between continent vs. incontinent patients (p = 0.4). In separate multivariable logistic regression models, coronal (odds ratio (OR): 1.35) and sagittal (OR: 1.67) USL, but not Lee-type, were independent predictors for mid-term continence. Conclusion: USL, but not apex anatomy, in preoperative mpMRI was associated with higher rates of urinary continence at mid-term follow-up.
Background: To test for differences in complication rates, in-hospital mortality, length of stay (LOS) and total hospital costs (THCs) in patients treated with neoadjuvant chemotherapy (NAC) prior to radical cystectomy (RC). Methods: Within the National (Nationwide) Inpatient Sample (NIS) database (2016–2019), we identified RC-treated, non-metastatic, lymph-node negative bladder cancer patients, stratified by NAC status. Trend analyses, multivariable logistic, multivariable Poisson and multivariable linear regression models were used. Results: We identified 4347 RC-treated bladder cancer patients. Of those, 805 (19%) received NAC prior to RC. Overall, complications rates did not differ (65 vs. 66%; p = 0.7). However, NAC patients harbored lower rates of surgical site (6 vs. 9%), cardiac (13 vs. 19%) and genitourinary (5.5 vs. 9.7%) complications. In-hospital mortality (<1.7 vs. 1.8%) and LOS (6 vs. 7 days) was lower in NAC patients (all p < 0.05). Moreover, NAC was an independent predictor of shorter LOS in multivariable Poisson regression models (Risk ratio: 0.86; p < 0.001) and an independent predictor for higher THCs in multivariable linear regression models (Odds ratio: 1474$; p = 0.02). Conclusion: NAC was not associated with higher complication rates and in-hospital mortality. Contrary, NAC was associated with shorter LOS, yet moderately higher THCs. The current analysis suggests no detriment from NAC in the context of RC.
Localized prostate cancer exhibits multiple genomic alterations and heterogeneity at the proteomic level. Single-cell technologies capture important cell-to-cell variability responsible for heterogeneity in biomarker expression that may be overlooked when molecular alterations are based on bulk tissue samples. This study aims to identify prognostic biomarkers and describe the heterogeneity of prostate cancer and the associated microenvironment by simultaneously quantifying 36 proteins using single-cell mass cytometry analysis of over 1.6 million cells from 58 men with localized prostate cancer. We perform this task, using a high-dimensional clustering pipeline named Franken to describe subpopulations of immune, stromal, and prostate cells, including changes occurring in tumor tissues and high-grade disease that provide insights into the coordinated progression of prostate cancer. Our results further indicate that men with localized disease already harbor rare subpopulations that typically occur in castration-resistant and metastatic disease.
Objective: To analyze the influence of biopsy Gleason score on the risk for lymph node invasion (LNI) during pelvic lymph node dissection (PLND) in patients undergoing radical prostatectomy (RP) for intermediate-risk prostate cancer (PCa).
Materials and Methods: We retrospectively analyzed 684 patients, who underwent RP between 2014 and June 2020 due to PCa. Univariable and multivariable logistic regression, as well as binary regression tree models were used to assess the risk of positive LNI and evaluate the need of PLND in men with intermediate-risk PCa.
Results: Of the 672 eligible patients with RP, 80 (11.9%) men harbored low-risk, 32 (4.8%) intermediate-risk with international society of urologic pathologists grade (ISUP) 1 (IR-ISUP1), 215 (32.0%) intermediate-risk with ISUP 2 (IR-ISUP2), 99 (14.7%) intermediate-risk with ISUP 3 (IR-ISUP3), and 246 (36.6%) high-risk PCa. Proportions of LNI were 0, 3.1, 3.7, 5.1, and 24.0% for low-risk, IR-ISUP1, IR-ISUP 2, IR-ISUP-3, and high-risk PCa, respectively (p < 0.001). In multivariable analyses, after adjustment for patient and surgical characteristics, IR-ISUP1 [hazard ratio (HR) 0.10, p = 0.03], IR-ISUP2 (HR 0.09, p < 0.001), and IR-ISUP3 (HR 0.18, p < 0.001) were independent predictors for lower risk of LNI, compared with men with high-risk PCa disease.
Conclusions: The international society of urologic pathologists grade significantly influence the risk of LNI in patients with intermediate- risk PCa. The risk of LNI only exceeds 5% in men with IR-ISUP3 PCa. In consequence, the need for PLND in selected patients with IR-ISUP 1 or IR-ISUP2 PCa should be critically discussed.
Effect of chemotherapy on overall survival in contemporary metastatic prostate cancer patients
(2021)
Introduction: Randomized clinical trials demonstrated improved overall survival in chemotherapy exposed metastatic prostate cancer patients. However, real-world data validating this effect with large scale epidemiological data sets are scarce and might not agree with trials. We tested this hypothesis.
Materials and Methods: We identified de novo metastatic prostate cancer patients within the Surveillance, Epidemiology, and End Results (SEER) database (2014-2015). Kaplan-Meier plots and Cox regression models tested for overall survival differences between chemotherapy-exposed patients vs chemotherapy-naïve patients. All analyses were repeated in propensity-score matched cohorts. Additionally, landmark analyses were applied to account for potential immortal time bias.
Results: Overall, 4295 de novo metastatic prostate cancer patients were identified. Of those, 905 (21.1%) patients received chemotherapy vs 3390 (78.9%) did not. Median overall survival was not reached at 30 months follow-up. Chemotherapy-exposed patients exhibited significantly better overall survival (61.6 vs 54.3%, multivariable HR:0.82, CI: 0.72-0.96, p=0.01) at 30 months compared to their chemotherapy-naïve counterparts. These findings were confirmed in propensity score matched analyses (multivariable HR: 0.77, CI:0.66-0.90, p<0.001). Results remained unchanged after landmark analyses were applied in propensity score matched population.
Conclusions: In this contemporary real-world population-based cohort, chemotherapy for metastatic prostate cancer patients was associated with better overall survival. However, the magnitude of overall survival benefit was not comparable to phase 3 trials.
Integrin receptors contribute to hepatocellular carcinoma (HCC) invasion, while AKT-mTOR signaling controls mitosis. The present study was designed to explore the links between integrins and the AKT-mTOR pathway and the CDK-Cyclin axis. HCC cell lines (HepG2, Huh7, Hep3B) were stimulated with soluble collagen or Matrigel to activate integrins, or with insulin-like growth factor 1 (IGF1) to activate AKT-mTOR. HCC growth, proliferation, adhesion, and chemotaxis were evaluated. AKT/mTOR-related proteins, proteins of the CDK-Cyclin axis, focal adhesion kinase (FAK), and integrin-linked kinase (ILK) were determined following IGF1-stimulation or integrin knockdown. Stimulation with collagen or Matrigel increased tumor cell growth and proliferation. This was associated with significant alteration of the integrins α2, αV, and β1. Blockade of these integrins led to cell cycle arrest in G2/M and diminished the number of tumor cell clones. Knocking down the integrins α2 or β1 suppressed ILK, reduced FAK-phosphorylation and diminished AKT/mTOR, as well as the proteins of the CDK-Cyclin axis. Activating the cells with IGF1 enhanced the expression of the integrins α2, αV, β1, activated FAK, and increased tumor cell adhesion and chemotaxis. Blocking the AKT pathway canceled the enhancing effect of IGF on the integrins α2 and β1. These findings reveal that HCC growth, proliferation, and invasion are controlled by a fine-tuned network between α2/β1-FAK signaling, the AKT-mTOR pathway, and the CDK–Cyclin axis. Concerted blockade of the integrin α2/β1 complex along with AKT-mTOR signaling could, therefore, provide an option to prevent progressive dissemination of HCC.